Table 1. Demographic characteristics of nursing home residents by infection status and mRNA COVID-19 vaccine type at enrollment—Georgia, December 2020–July 2022, n = 37.
| Characteristics | SARS-CoV-2 infected at enrollment * | SARS-CoV-2 infection-naive at enrollment † | Overall | ||||
|---|---|---|---|---|---|---|---|
| Pfizer (n = 23) | Moderna (n = 7) | Total (n = 30) | Pfizer (n = 5) | Moderna (n = 2) | Total (n = 7) | Total (n = 37) | |
| n % | n % | n % | n % | n % | n % | n % | |
| Age (median, Q1–Q3), years | 71.7 | 65.3 | 70.5 | 74 | 72.7 | 74 | 70.5 |
| (64.9–78.6) | (62.5–77.0) | (64.9–77.7) | (64.2–87.0) | (66.8–78.6) | (64.2–87.0) | (64.9–78.6) | |
| Sex | |||||||
| Male | 10 (43) | 5 (71) | 15 (50) | 1 (20) | 1 (50) | 2 (29) | 17 (46) |
| Female | 13 (57) | 2 (29) | 15 (50) | 4 (80) | 1 (50) | 5 (71) | 20 (54) |
| Race | |||||||
| White | 17 (74) | 3 (43) | 20 (67) | 4 (80) | 0 (0) | 4 (57) | 24 (65) |
| Black | 6 (26) | 4 (57) | 10 (33) | 1 (20) | 2 (100) | 3 (43) | 13 (35) |
| Ethnicity | |||||||
| Non-Hispanic | 20 (87) | 7 (100) | 27 (90) | 4 (80) | 2 (100) | 6 (86) | 34 (92) |
| Hispanic | 1 (4) | 0 | 1 (3) | 0 | 0 | 0 | 1 (3) |
| Not Specified | 2 (9) | 0 | 2 (7) | 1 (20) | 0 | 1 (14) | 2 (5) |
| Duration of stay in the facility (median, Q1–Q3), months | 20.8 | 21.5 | 21.2 | 15.4 | 69.3 | 15.4 | 20.8 |
| (10.7–41.1) | (13.1–52.4) | (10.8–41.1) | (13.7–25.4) | (0.8–137.8) | (13.3–30.1) | (11.9–38.6) | |
| Days between date of COVID-19 diagnosis to first mRNA COVID-19 vaccine dose, median (Q1–Q3) | 90 | 202 | 105 | ||||
| (80–105) | (139–209) | (84–196) | |||||
| Days between first and second doses of mRNA COVID-19 vaccine (median, Q1–Q3) | 21 (21–22) | 31 (31–31) | 21 (21–31) | 23 (23–31) | 30 (28–31) | 28 (23–31) | 22 (21–31) |
| Underlying condition ‡ | |||||||
| ≥3 underlying conditions | 18 (78) | 4 (57) | 22 (73) | 5 (100) | 2 (100) | 7 (100) | 29 (78) |
| Hypertension | 19 (83) | 4 (57) | 23 (77) | 5 (100) | 2 (100) | 7 (100) | 30 (81) |
| Cerebrovascular accident | 9 (39) | 3 (43) | 12 (40) | 2 (40) | 2 (100) | 4 (57) | 16 (43) |
| Heart failure | 8 (35) | 1 (14) | 9 (30) | 1 (20) | 2 (100) | 3 (43) | 12 (32) |
| Coronary artery disease | 8 (35) | 1 (14) | 9 (30) | 2 (40) | 0 (0) | 2 (29) | 11 (30) |
| Neurologic disease | 11 (48) | 5 (71) | 16 (53) | 2 (40) | 2 (100) | 4 (57) | 20 (54) |
| Diabetes mellitus | 8 (35) | 1 (14) | 9 (30) | 2 (40) | 0 | 2 (29) | 11 (30) |
| Chronic kidney disease | 6 (26) | 1 (14) | 7 (23) | 1 (20) | 0 | 1 (14) | 8 (22) |
| Asthma | 2 (9) | 0 | 2 (7) | 0 | 1 (50) | 1 (14) | 3 (8) |
| Cancer | 3 (13) | 0 | 0 | 0 | 0 | 0 | 3 (8) |
| Chronic obstructive pulmonary disease (non-asthma) | 3 (13) | 0 | 3 (10) | 0 | 0 | 0 | 3 (8) |
| Chronic obstructive pulmonary disease (non-asthma) | 3 (13) | 0 | 3 (10) | 0 | 0 | 0 | 3 (8) |
| 0 | |||||||
| Former/current smoker | 14 (61) | 5 (72) | 19 (64) | 2 (40) | 1 (50) | 3 (43) | 22 (60) |
*A SARS-CoV-2 infected participant was defined at enrollment as a participant with infection documented in the electronic health record or confirmed by laboratory testing using real-time reverse-transcriptase polymerase chain reaction (rRT-PCR) or point of care BinaxNOW™ COVID-19 Ag Card antigen test (BinaxNOW).
†An infection-naïve participant was defined as having an absence of a documented SARS-CoV-2 infection and negative SARS-CoV-2 laboratory test results, including seronegative for anti-N antibody.
‡Underlying conditions are presented in descending order based on the ‘Overall’ column.